KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

• Main Authors: Kuhen, K.L, Chatterjee, A.K, Rottmann, M
• Other Authors: MICROBIOLOGY AND IMMUNOLOGY
• Format: Article
• Published: American Society for Microbiology 2020
• Subjects: antimalarial agent; artesunate; chloroquine; imidazole derivative; kaf 156; kaf156; mefloquine; piperazine derivative; unclassified drug; KAF156; animal experiment; animal model; Anopheles; antimalarial activity; antimalarial drug susceptibility; article; controlled study; disease elimination; dose time effect relation; drug dose comparison; drug efficacy; drug safety; female; genetic strain; human; human cell; IC 50; in vitro study; in vivo study; malaria control; malaria falciparum; mouse; multiple drug dose; nonhuman; parasite clearance; parasite transmission; Plasmodium falciparum; Plasmodium vivax malaria; priority journal; rodent malaria; schizont; single drug dose; sporozoite; treatment response; animal; drug effects; IC50; Institute for Cancer Research mouse; Malaria, Falciparum; transmission; Animals; Antimalarials; Imidazoles; Inhibitory Concentration 50; Mice; Mice, Inbred ICR; Piperazines; Sporozoites
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/180171
• Institution: National University of Singapore

10.1128/AAC.02727-13